SCA Pharmaceuticals is a recognized leader in the field of sterile compounding, thanks to our leadership team with three decades of experience. SCA specializes in preparing sterile pharmaceuticals customized for hospitals pharmacies and healthcare facilities nationwide. Our products and services have consistently proven to significantly increase efficiencies and reduce costs to these organizations. Our dedicated and talented team members are passionate about providing the highest quality products and service to our valued customers.
SCA Pharmaceuticals is committed to quality by design, compliance with FDA guidelines, upholding the highest ethical standards in the industry, and ensuring the best clinical care and patient safety. SCA Pharmaceuticals has invested in the latest technological advancements in sterile pharmaceutical production and quality control with Rapid Microbiological capabilities.
Mr. Boyer has served in technical, commercial and executive roles in the pharmaceutical industry for more than 25 years with a specific focus in contract manufacturing for both drug substance and sterile drug product. For the last decade, he has been involved in sterile drug product manufacturing, most recently as the Senior Vice President of Drug Product Manufacturing at AMRI, a global contract research and manufacturing organization. Mr. Boyer joined AMRI in 2014 upon AMRI’s acquisition of Oso BioPharmaceuticals, where he served as President and CEO and as a member of the Board of Directors.
Active in trade groups and educational institutions that support the pharmaceutical and biopharmaceutical industry, Mr. Boyer serves on the board of directors of the Drug, Chemical & Allied Trades Association (DCAT) and is now on the executive committee as its President. He has also served on the external advisory board for the University of New Mexico’s chemistry and biology department and been an active member of other professional organizations, including the American Association of Pharmaceutical Scientists, the Parenteral Drug Association and the Society of Chemical Manufacturers and Affiliates,
Mr. Boyer has a bachelor’s in chemistry/physics and a master’s in biochemistry from Hardin-Simmons University and Texas Tech University.
Matt Graves is a graduate of the Sam M. Walton College of Business at the University of Arkansas. Through his strategic marketing and sales initiatives, SCA has grown into a nationwide force in the pharmaceutical compounding industry. Matt is also in charge of all contracts, pricing structures, special projects and initiatives, as well as coordinating day to day with SCA's leadership team.
Matt White received his Doctor of Pharmacy degree from the University of Arkansas College of Pharmacy where he earned admission to Rho Chi for his high academic achievements. Matt has advanced training and certification in "High Risk Sterile Compounding" from the University of Tennessee College of Pharmacy. He has multiple years of sterile compounding experience and previously worked in one of the largest Acute Care Hospital facilities in the South.
Michelle Wood is responsible for growing SCA across the country. Michelle consults with Directors of Pharmacy, Anesthesiologists, Surgeons, Clinical Coordinators, Purchasing/Materials Management, and other key contacts for outsourcing over 250 drugs ranging from Class II through Class IV drugs. Michelle spent many years developing relationships with many different Corporate GPOs, IDNs, and other C-Level key contacts nationwide, and has implemented a number of large corporate purchasing contracts. She has helped launch many new products for SCA Pharmaceuticals and continues to lead SCA’s marketing team into the future.